TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from EVE Health Group Limited ( (AU:EVE) ) is now available.
EVE Health Group Limited has signed a Patient Support Telehealth Services Agreement with hubMed Pty Ltd to enhance care for patients using its products, Dyspro™ and Libbo™, for women’s and men’s health conditions. This agreement aims to improve continuity of care and patient confidence by providing accessible telehealth consultations with registered nurses, reinforcing the safe use of EVE’s therapies. The initiative is expected to address significant unmet needs in both women’s and men’s health, potentially improving patient outcomes and adherence to treatment.
More about EVE Health Group Limited
EVE Health Group Limited operates in the healthcare industry, focusing on therapeutic products for women’s and men’s health. The company’s primary products include Dyspro™ for dysmenorrhoea and Libbo™ for erectile dysfunction, with a market focus on enhancing patient care through telehealth services and support programs.
Average Trading Volume: 653,718
Technical Sentiment Signal: Sell
Current Market Cap: A$7.35M
See more insights into EVE stock on TipRanks’ Stock Analysis page.